For the first time, a drug has been approved to directly target the KRAS G12C mutation in lung cancer — a change that was thought to be impossible for decades because of how the protein behaves.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of all prior attempts to target KRAS G12C would confirm that no prior agent received FDA approval for this indication.
A systematic review of all clinical trials, regulatory submissions, and published literature from 1980 to 2021 evaluating agents targeting KRAS G12C, including covalent inhibitors, GTP-competitive compounds, and indirect inhibitors, with primary outcome being FDA approval status for NSCLC.
Not applicable — this is a historical claim, not a therapeutic comparison.
Not applicable.
Not applicable — this is a regulatory milestone, not a clinical outcome.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.